Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15757
Abstract: NAVIGATE clinical trial demonstrated a higher rate of Psoriasis Assesment Severity Index (PASI)90 response in patients treated with guselkumab when compared to ustekinumab and an improved response in those who switched from ustekinumab to guselkumab… read more here.
Keywords: ustekinumab guselkumab; trial; pasi; dosage regime ... See more keywords